✦ LIBER ✦

Fall in Diffusing Capacity Associated With Induction Therapy for Lung Cancer: A Predictor of Postoperative Complication?

✍ Scribed by Shin-ichi Takeda; Yasunobu Funakoshi; Yoshihisa Kadota; Masaru Koma; Hajime Maeda; Satoko Kawamura; Yoko Matsubara

Book ID: 116261792
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 106 KB
Volume: 82
Category: Article
ISSN: 0003-4975
DOI: 10.1016/j.athoracsur.2006.01.045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

B-Type Natriuretic Peptide as a Predicto

B-Type Natriuretic Peptide as a Predictor of Postoperative Cardiopulmonary Complications in Elderly Patients Undergoing Pulmonary Resection for Lung Cancer

✍ Takashi Nojiri; Masayoshi Inoue; Kazuhiro Yamamoto; Hajime Maeda; Yukiyasu Takeu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Dose–Volume Analysis of Predictors for G

Dose–Volume Analysis of Predictors for Gastrointestinal Complications in Patients With Cervical Cancer Treated With Postoperative Pelvic Radiation Therapy and Concurrent Nedaplatin-Based Chemotherapy

✍ Isohashi, F.; Akino, Y.; Otani, Y.; Suzuki, O.; Seo, Y.; Yoshioka, Y.; Ogawa, K. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 48 KB

522 High dose-rate (HDR) endobronchial b

522 High dose-rate (HDR) endobronchial brachytherapy associated or not with previous Nd-YAG laser therapy for lung cancer: Results and complications of a prospective study

✍ Carvalho, B.A.; Aisen, S.; Chavantes, M.C.; Pedreira, W.L.; Takagaki, T.Y.; Hadd 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 165 KB

KRAS Mutation Is an Important Predictor

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer

✍ Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A. C.; Ozburn, N. C.; Liu, 📂 Article 📅 2007 🏛 American Association for Cancer Research 🌐 English ⚖ 196 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB